Старение. Профессиональный врачебный подход

   162. Robins L. How recognizing comorbidities in psychopathology may lead to an improved research nosology // Clinical Psychology: Science and Practice, 1994; 1, 93–95.

   163. Rose M.R. Evolutionary Biology of Aging. N.Y.: Oxford Univ. Press, 1991. 221 p.

   164. Rossoni G., Bernareggi M., De Gennaro Colonna V. et al. Lercanidipine protects the heart from low – flow isch emia damage and antagonizes the vasopressor activity of endothelin–1. – J. Cardiovascul. Pharmacol., 1997; 29 (suppl. 1): S. 41–S47.

   165. Rozzini R., Frisoni G.B., Ferrucci L., Barbisoni P., Sabatini T., Ranieri P., Guralnik J.M., Trabucchi M. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity // Age Ageing, 2002; Jul;31(4): 277–85.

   166. Rutten B.P.F., Korr H., Steinbusch H.W. M., Schmitz С. The aging brain: L less neurons could be better// Mech. Ageing Dev. 2003. Vol. 124. P. 349–355.

   167. Salisbury C., Johnson L., Purdy S., Valderas J.M., Montgomery A.A. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2011 Jan; 61(582): e12–21.

   168. Sanderson W.C., Beck A.T., Beck J. Syndrome comorbidity in patients with major depression or dysthymia: Prevalence and temporal relationships // Am J Psychiatry, 1990; 14 7: 10–25–1028.

   169. Schöfer I., von Leitner E.C., Schön G., Koller D., Hansen H., Kolonko T., Kaduszkiewicz H., Wegscheider K., Glaeske G., van den Bussche H. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. PLoS One. 2010. Dec 29; 5(12): e15941.

   170. Scheidt-Nave C., Richter S., Fuchs J., Kuhlmey A. Challenges to health research for aging populations using the example of «multimorbidity».Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010. May; 53(5): 441-50.

   171. Schellevis F.G., Velden J. vd, Lisdonk E. vd Comorbidity of chronic diseases in general practice // J Clin Epidemiol, 1993; 46: 469–473.

   172. Schofield R.S., Hill J.A. The use of ranolazine in cardiovascular disease // Expert. Opin. Investig. Drugs. – 2002. – Vol. 11, № 1. – P. 117–123.

   173. Schtessinge r D., Van Zant G. Does functional depletion of stem cells drive aging? Mech. Ageing Dev. 2001. Vol. 122.P. 1537–1553.

   174. Schuler J, Dückelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria.

   175. Schulz-Aellen M, – F. Aging and Human Longevity. Boston: Birkhauser, 1997. 283 p.

   176. Schulze P. Christian. Myocardial lipid accumulation and lipotoxicity in heart failure. // J Lipid Res 2009; 50: 2137-8.

   177. Schuster E. Polymorbidity and therapy in the aged. Z Arztl Fortbild (Jena). 1977 Jul 15;71(14):673-4.

   178. Schwartz M. W., Woods S. C., Porte D. et al. Central nervous system control of food intake Nature. 2000. Vol. 404. P. 661–671.

   179. Scirica B.M., Morrow D.A., Hod H. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non – ST-Segment – Elevation Acute Coronary Syndrome. Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non – ST-Elevation Acute Coronary Syndrome – Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial // Circulation. October 9, 2007;116:1647–1652.

   180. Shimokawa I., Higanti Y., Utsuyama M. et al. Life span extension by reduction in growth hormone-insulin-like growth factor-1 axis in a transgenic rat model Am. J. Pathol. 2002. Vol. 160. P. 2259–2265.

   181. Siliprandi N., Di Lisa F., Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism // Cardiovasc. Drugs Ther. – 1991. – Vol. 5 (Suppl. 1). – P. 17–24.

   182. Skulachev V. P. Programmes death phenomena: from organelle to organism Ann. N.Y. Acad. Sci. 2O02. Vol. 959. P. 214–237.

   183. SohalR. S. Role of oxida tve stress and protein oxidation in the aging process. Free Radical Biol. Med. 2O02. Vol. 33. P. 37–44.

   184. Sparrow C.P., Burton C.A., Hernandez M. et al. Simvastatin has anti-inflammatory end antiatherosclerotic activities independent of plasma cholesterol lowering //Arterioscler. Thromb Vasc Biol. – 2001. – Vol.21. – Р.115–121.

   185. Starfield B., Lemke K.W., Bernhardt T. Comorbidity: Implications for the Importance of Primary Care in Case Management // Ann Fam Med, 2003; 1(1):8-14

   186. Steger Я W., Bartke A., Cecim M. Premature aging in transgenic mice exressing growth hormone genes//J. Repr. Fertil. Supp]. 1993. Vol.46. P. 61–75.

   187. Stewart S. A., Weinberg R. A. Senescence: does it all happen at the ends? Qn-cogene. 2O02. Vol. 21. P. 627–630.

   188. Stier D.M., Greenfield S., Lubeck D.P., Dukes K.A., Flanders S.C., Henning J.M., Weir J., Kaplan S.H. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer // Urology, 1999; Sep; 54(3):424-9